CN117297005A - 一种护肝醒酒组合物及其制备方法与应用 - Google Patents
一种护肝醒酒组合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN117297005A CN117297005A CN202311326995.6A CN202311326995A CN117297005A CN 117297005 A CN117297005 A CN 117297005A CN 202311326995 A CN202311326995 A CN 202311326995A CN 117297005 A CN117297005 A CN 117297005A
- Authority
- CN
- China
- Prior art keywords
- extract
- liver
- composition
- protecting
- sobering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 210000000582 semen Anatomy 0.000 claims abstract description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 32
- 229910001868 water Inorganic materials 0.000 claims abstract description 25
- 239000007788 liquid Substances 0.000 claims abstract description 22
- 230000001954 sterilising effect Effects 0.000 claims abstract description 18
- 238000002156 mixing Methods 0.000 claims abstract description 16
- 238000011049 filling Methods 0.000 claims abstract description 14
- 239000008367 deionised water Substances 0.000 claims abstract description 9
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 9
- 238000000605 extraction Methods 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 238000004140 cleaning Methods 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 239000011521 glass Substances 0.000 claims abstract description 7
- 239000011265 semifinished product Substances 0.000 claims abstract description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 58
- 210000004185 liver Anatomy 0.000 claims description 49
- 235000003805 Musa ABB Group Nutrition 0.000 claims description 23
- 235000015266 Plantago major Nutrition 0.000 claims description 23
- 238000001035 drying Methods 0.000 claims description 23
- 206010067125 Liver injury Diseases 0.000 claims description 22
- 244000046146 Pueraria lobata Species 0.000 claims description 22
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 22
- 241000220317 Rosa Species 0.000 claims description 22
- 239000000706 filtrate Substances 0.000 claims description 22
- 244000010000 Hovenia dulcis Species 0.000 claims description 19
- 235000008584 Hovenia dulcis Nutrition 0.000 claims description 19
- 231100000753 hepatic injury Toxicity 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 241000196324 Embryophyta Species 0.000 claims description 8
- 230000002633 protecting effect Effects 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 241000238631 Hexapoda Species 0.000 claims description 6
- 240000002547 Rosa roxburghii Species 0.000 claims description 6
- 235000000640 Rosa roxburghii Nutrition 0.000 claims description 6
- 241000607479 Yersinia pestis Species 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 3
- 240000008790 Musa x paradisiaca Species 0.000 claims 5
- 235000013402 health food Nutrition 0.000 claims 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 33
- 210000005228 liver tissue Anatomy 0.000 description 19
- 241001127637 Plantago Species 0.000 description 18
- 102000019197 Superoxide Dismutase Human genes 0.000 description 18
- 108010012715 Superoxide dismutase Proteins 0.000 description 18
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 15
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 15
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 15
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 14
- 108010082126 Alanine transaminase Proteins 0.000 description 14
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 13
- 230000001476 alcoholic effect Effects 0.000 description 13
- 229940118019 malondialdehyde Drugs 0.000 description 13
- 230000001154 acute effect Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 12
- 210000005229 liver cell Anatomy 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 235000013305 food Nutrition 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 6
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 5
- 206010019133 Hangover Diseases 0.000 description 5
- 208000010796 X-linked adrenoleukodystrophy Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 231100000915 pathological change Toxicity 0.000 description 5
- 230000036285 pathological change Effects 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000004792 oxidative damage Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 2
- 229940043175 silybin Drugs 0.000 description 2
- 235000014899 silybin Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- -1 AST) Proteins 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 235000010955 Hovenia acerba Nutrition 0.000 description 1
- 241001533134 Hovenia acerba Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001534110 Lactarius <percoid fish> Species 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 241001499733 Plantago asiatica Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002075 anti-alcohol Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/13—Preparation or pretreatment of starting material involving cleaning, e.g. washing or peeling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/31—Extraction of the material involving untreated material, e.g. fruit juice or sap obtained from fresh plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种护肝醒酒组合物及其制备方法与应用。所述护肝醒酒组合物包括按如下主要原料:刺梨原汁、葛根提取物、枳椇子提取物、车前草提取物、水。其制备方法包括:(1)刺梨经清洗、破碎、物理压榨、过滤后得到刺梨原汁;(2)提取物制备:用乙醇‑水作为提取溶剂提取枳椇子提取物和葛根提取物,用去离子水作为提取溶剂提取车前子;(3)混合:将刺梨原汁、枳椇子提取物、葛根提取物、车前草提取物与水按组方量混合均匀;(3)灌装:将上述混合好的提取物混合液灌装于玻璃瓶中;(4)杀菌:将上述灌装好的半成品进行高温杀菌后得到成品护肝醒酒组合物(ZHW)。
Description
技术领域
本发明涉及食品、保健食品、药品加工技术领域,特别涉及一种护肝醒酒组合物及其制备方法与应用。
背景技术
近年来,我国酒精性肝病(alcoholic liver disease,ALD)发病率逐年上升的势头仍在增加[1]。ALD是由于酒精在肝脏中代谢不通畅所导致的疾病[2]。长期过量饮酒,不仅会导致酒精性肝损伤、酒精性脂肪肝、肝纤维化,量积聚到一定程度时会恶化成肝硬化和肝癌,对人们的身体健康产生重大危害[3]。时下,戒酒、药物治疗、营养物补充仍然是临床上预防和治疗ALD主要采用的方案,这些方式中戒酒的困难比较大,药物治疗会产生一定的副作用和不良反应,营养物支持的效果一般[4]。所以,寻找和开发天然的护肝解酒产品意义深刻。
刺梨(Rose roxburghii Tratt)为蔷薇科多年生落叶灌木缫丝花的果实,是贵州省十二大农业特色优势产业之一,其作为药食两用资源已有多年历史[5]。刺梨鲜果中含有丰富的活性物质和微量元素,如VC、氨基酸、超氧化物歧化酶(superoxide dismutase,SOD)、多糖等,且具有抗氧化性、降血糖、降血脂、抗肿瘤等多种生物活性[6]。Rensburg[7]等研究表明机体补充刺梨能提高体内SOD和还原型谷胱甘肽(glutathione,GSH)的水平,而SOD、GSH可以清除乙醇在机体中代谢不畅产生的大量自由基[8],从而起到解酒保肝的作用。葛根提取物(Puerariae lobatae)是豆科植物野葛的干燥块根,有解表、退热、解酒毒等功效[9];枳椇子提取物为鼠李科枳椇属植物枳椇(Hovenia acerba)的肉质果柄和干燥成熟的种子,有清热利尿,解酒毒之功效[10];车前草提取物为车前科植物车前(Plantagoasiatica)的干燥全草,具有利尿通淋、凉血解毒、祛痰的功效[11];并且有文献报道葛根提取物、枳椇子提取物的提取物具有较好的解酒、护肝等功效[12,13],车前草提取物的提取物具有较好的利尿作用[14]。但目前将刺梨、葛根提取物、枳椇子提取物、车前草提取物四种植物组合物应用在对小鼠急性酒精性肝损伤的保护作用方面的研究还未见报道。
因此,本实验以贵州特色资源刺梨和药食同源的传统解酒护肝、利尿植物葛根提取物、枳椇子提取物、车前草提取物为主要原料制成护肝醒酒组合物,从肝脏指数、血清及肝脏生化指标、病理切片等方面来评价ZHW对急性酒精性肝损伤小鼠的保护作用。
发明内容
本发明的目的在于提供一种护肝醒酒组合物。
本发明的另一目的在于提供一种护肝醒酒组合物的制备方法。
本发明的另一目的在于提供一种护肝醒酒组合物或护肝醒酒组合物的制备方法制备所得成品护肝醒酒组合物在制备醒酒、护肝饮料或食品中的应用,以及在制备醒酒药物、预防或治疗护肝损伤药物中的应用。
为了实现本发明目的,本发明采用如下技术方案和步骤实现:
本发明所述的护肝醒酒组合物,由以下重量份的原料组成:刺梨原汁30-40份、葛根提取物0.1-0.5份、枳椇子提取物0.3-0.9份、车前草提取物0.2-0.8份、水58-69份。
优选的,本发明所述组合物由以下重量份的原料组成:刺梨原汁32-38份、葛根提取物0.2-0.4份、枳椇子提取物0.5-0.7份、车前草提取物0.4-0.6份、水61-66份。
进一步优选的,本发明所述组合物由以下重量份的原料组成:刺梨原汁35份、葛根提取物0.33份、枳椇子提取物0.67份、车前草提取物0.5份、水63.5份。
本发明所述的护肝醒酒组合物的制备方法,包括如下步骤:
(1)刺梨原汁的制备:挑选品质优良,无病虫害的刺梨鲜果经清洗干净、物理破碎、低温物理压榨、过滤后得到刺梨原汁;
(2)提取物制备:
枳椇子提取物以65-75%(v/v)乙醇作为提取溶剂,料液比1:8-12提取1-3次,0.5-1.5h/次,滤液减压浓缩,干燥得到枳椇子提取物;
车前草提取物以去离子水作为提取溶剂,料液比1:4-8提取1-3次,0.5-1.5h/次,滤液减压浓缩,干燥得到车前草提取物;
葛根提取物以80%(v/v)乙醇作为提取溶剂,料液比1:8-12提取1-3次,0.5-1.5h/次,滤液减压浓缩,干燥得到葛根提取物;
(3)混合:将刺梨原汁、枳椇子提取物、葛根提取物、车前草提取与水按组方量物混合均匀;
(4)灌装:将上述混合好的提取物混合液分别灌装于30mL玻璃瓶中;
(5)杀菌:将上述灌装好的半成品进行高温杀菌后得到成品护肝醒酒组合物(ZHW)。
本发明所述步骤(2)提取物制备为:
枳椇子提取物以70%(v/v)乙醇作为提取溶剂,料液比1:10提取2次,1h/次,滤液减压浓缩,干燥得到枳椇子提取物提取物;
车前草提取物以去离子水作为提取溶剂,料液比1:4提取2次,1h/次,滤液减压浓缩,干燥得到车前草提取物提取物;
葛根提取物以80%(v/v)乙醇作为提取溶剂,料液比1:10提取2次,1h/次,滤液减压浓缩,干燥得到葛根提取物提取物。
本发明所述刺梨原汁、提取物的占比为:35%刺梨原汁、1.5%提取物。
本发明步骤(3)混合中所述枳椇子提取物、葛根提取物、车前草提取物的质量比为:枳椇子提取物:葛根提取物:车前草提取物=1:2:1.5。
本发明步骤(4)中所述高温杀菌条件为:温度85℃,杀菌时间25分钟。
本发明所述的护肝醒酒组合物或所述制备方法制备所得的成品护肝醒酒组合物在制备醒酒、护肝的饮料中的应用。
本发明所述的护肝醒酒组合物或所述制备方法制备所得的成品护肝醒酒组合物在制备醒酒、护肝的保健食品中的应用。
本发明所述的护肝醒酒组合物或所述制备方法制备所得的成品护肝醒酒组合物在制备醒酒药物或预防和治疗护肝损伤药物中的应用。
本发明有益效果:
1.本发明制备所得产品护肝醒酒组合物(ZHW)可有效预防和改善酒精性肝损伤,效果显著。通过动物实验,建立急性酒精性肝损伤模型,计算肝脏指数,测定血清中甘油三酯(TG)、丙氨酸氨基转移酶(ALT)、谷草转氨酶(AST)和肝组织中超氧化物歧化酶(SOD)、丙二醛(MDA)、乙醇脱氢酶(ADH)、乙醛脱氢酶(ALDH)的水平变化及通过肝组织病理切片分析其形态变化,结果表明:
(1)与模型组相比,ZHW高剂量组肝脏指数、TG含量、MDA含量显著降低12.33%、48.35%、39.10%;SOD、ALDH、ADH水平显著提高18.61%、44.59%、124.61%;AST、ALT水平显著降低32.26%、40.71%;
(2)小鼠肝组织病理切片结果显示,ZHW各剂量组小鼠受损肝脏均得到不同程度改善。
综上所述,ZHW对酒精所致的急性肝损伤小鼠的肝脏肿大、脂质代谢紊乱、肝脏氧化应激具有显著改善效果,可有效预防和改善急性酒精性肝损伤。
2.本发明制备方法简单,制备所得护肝醒酒组合物无副作用和不良反应。
附图说明
图1:ZHW对小鼠肝脏指数的影响
图2:ZHW对小鼠血清中TG水平的影响
图3:ZHW对小鼠血清中ALT水平的影响
图4:ZHW对小鼠血清中AST水平的影响
图5:ZHW对小鼠肝组织中SOD水平的影响
图6:ZHW对小鼠肝组织中MDA水平的影响
图7:ZHW对小鼠肝组织中ADH水平的影响
图8:ZHW对小鼠肝组织中ALDH水平的影响
图9:ZHW对小鼠肝组织病理变化的影响(10×20)(其中,K:空白组,M:模型组,Y:阳性组,D:低剂量组,Z:中剂量组,G:高剂量组)
具体实施方式
实施例1护肝醒酒组合物
组成:刺梨35份、葛根提取物0.33份、枳椇子提取物0.67份、车前草提取物0.5份、水63.5份。
实施例2护肝醒酒组合物
组成:刺梨30份、葛根提取物0.1份、枳椇子提取物0.3份、车前草提取物0.6份、水69份。
实施例3护肝醒酒组合物
组成:刺梨40份、葛根提取物0.5份、枳椇子提取物0.9份、车前草提取物0.6份、水58份。
实施例4护肝醒酒组合物
组成:刺梨35份、葛根提取物0.2份、枳椇子提取物0.4份、车前草提取物0.3份、水64.1份。
实施例5护肝醒酒组合物
组成:刺梨35份、葛根提取物0.3份、枳椇子提取物0.6份、车前草提取物0.45份、水63.65份。
实施例6护肝醒酒组合物
组成:刺梨35份、葛根提取物0.4份、枳椇子提取物0.8份、车前草提取物0.6份、水63.2份。
实施例7护肝醒酒组合物
组成:刺梨33份、葛根提取物0.4份、枳椇子提取物0.5份、车前草提取物0.6份、水65.5份。
实施例8护肝醒酒组合物
组成:刺梨38份、葛根提取物0.33份、枳椇子提取物0.67份、车前草提取物0.5份、水63.5份。
实施例9护肝醒酒组合物
组成:刺梨32份、葛根提取物0.33份、枳椇子提取物0.67份、车前草提取物0.5份、水66.5份。
实施例10护肝醒酒组合物
组成:刺梨36份、葛根提取物0.33份、枳椇子提取物0.67份、车前草提取物0.5份、水62.5份。
实施例1-10护肝醒酒组合物用于以下制备方法
实施例11护肝醒酒组合物的制备方法
(1)刺梨原汁的制备:挑选品质优良,无病虫害的刺梨鲜果经清洗干净、物理破碎、低温物理压榨、过滤后得到刺梨原汁;
(2)提取物制备:
枳椇子提取物以70%(v/v)乙醇作为提取溶剂,料液比1:10提取2次,1h/次,滤液减压浓缩,干燥得到枳椇子提取物;
车前草提取物以去离子水作为提取溶剂,料液比1:4提取2次,1h/次,滤液减压浓缩,干燥得到车前草提取物;
葛根提取物以80%(v/v)乙醇作为提取溶剂,料液比1:10提取2次,1h/次,滤液减压浓缩,干燥得到葛根提取物;
(3)混合:将刺梨原汁、枳椇子提取物、葛根提取物、车前草提取物与水按组方量混合均匀;
(4)灌装:将上述混合好的提取物混合液分别灌装于30mL玻璃瓶中;
(5)杀菌:将上述灌装好的半成品进行高温杀菌后得到成品护肝醒酒组合物(ZHW)。
实施例12护肝醒酒组合物的制备方法
(1)刺梨原汁的制备:挑选品质优良,无病虫害的刺梨鲜果经清洗干净、物理破碎、低温物理压榨、过滤后得到刺梨原汁;
(2)提取物制备:
枳椇子提取物以65%(v/v)乙醇作为提取溶剂,料液比1:8提取1次,0.5h/次,滤液减压浓缩,干燥得到枳椇子提取物;
车前草提取物以去离子水作为提取溶剂,料液比1:6提取1次,0.5h/次,滤液减压浓缩,干燥得到车前草提取物;
葛根提取物以75%(v/v)乙醇作为提取溶剂,料液比1:8提取1次,0.5h/次,滤液减压浓缩,干燥得到葛根提取物;
(3)混合:将刺梨原汁、枳椇子提取物、葛根提取物、车前草提取物与水按组方量混合均匀;
(4)灌装:将上述混合好的提取物混合液分别灌装于30mL玻璃瓶中;
(5)杀菌:将上述灌装好的半成品进行高温杀菌后得到成品护肝醒酒组合物(ZHW)。
实施例13护肝醒酒组合物的制备方法
(1)刺梨原汁的制备:挑选品质优良,无病虫害的刺梨鲜果经清洗干净、物理破碎、低温物理压榨、过滤后得到刺梨原汁;
(2)提取物制备:
枳椇子提取物以75%(v/v)乙醇作为提取溶剂,料液比1:12提取3次,1.5h/次,滤液减压浓缩,干燥得到枳椇子提取物;
车前草提取物以去离子水作为提取溶剂,料液比1:8提取3次,1.5h/次,滤液减压浓缩,干燥得到车前草提取物;
葛根提取物以85%(v/v)乙醇作为提取溶剂,料液比1:12提取3次,1.5h/次,滤液减压浓缩,干燥得到葛根提取物;
(3)混合:将刺梨原汁、枳椇子提取物、葛根提取物、车前草提取物与水按组方量混合均匀;
(4)灌装:将上述混合好的提取物混合液分别灌装于30mL玻璃瓶中;
(5)杀菌:将上述灌装好的半成品进行高温杀菌后得到成品护肝醒酒组合物(ZHW)。
为了进一步验证本发明的可行性及有效性,筛选出最佳方案,发明人进行了一系列的试验,具体如下:
1.材料与方法
1.1主要材料与试剂
刺梨,贵州赛斯刺梨大健康产业有限公司;葛根、车前草、枳椇子,贵阳中药材市场;超氧化物歧化酶(superoxide dismutase,SOD)、甘油三酯(triglyceride,TG)、丙二醛(malondialdehyde,MDA)、丙氨酸氨基转移酶(alanine aminotransferase,ALT)、乙醛脱氢酶(acetaldehyde dehydrogenase,ALDH)、谷草转氨酶(aspartate aminotransferase,AST)、乙醇脱氢酶(alcohol dehydrogenase,ADH)、总蛋白定量试剂盒,南京建成生物工程有限公司;水飞蓟宾胶囊,天津天士力制药股份有限公司,95%食用酒精,华兴食用酒精有限公司。
1.2主要仪器与设备
SKG1246打浆机,佛山艾诗凯奇电器有限公司;UV-1800紫外可见分光光度计,岛津仪器(苏州)有限公司;SCI-VS可调式混匀仪,济南博航生物技术有限公司;HC313型电子天平,上海花潮实业有限公司;5427R高速冷离心机,德国Eppendor公司;VICTOR Nivo酶标仪,珀金埃尔默企业管理有限公司;RM2016病理切片机,上海徕卡仪器有限公司。
1.3试验方法
1.3.1 ZHW的制备及及操作要点
操作要点:
(1)刺梨原汁的制备:挑选品质优良,无病虫害的刺梨鲜果经清洗干净、物理破碎、低温物理压榨、过滤后得到刺梨原汁;
(2)提取物制备:枳椇子提取物以70%(v/v)乙醇作为提取溶剂,料液比1:10提取2次,1h/次,滤液减压浓缩,干燥得到枳椇子提取物,得率10%(w/w);车前草提取物以去离子水作为提取溶剂,料液比1:4提取2次,1h/次;葛根提取物以80%(v/v)乙醇作为提取溶剂,料液比1:10提取2次,1h/次,后续步骤同上,得到车前草提取物,得率25%(w/w)、葛根提取物,得率3%(w/w)。
(3)混合:将刺梨原汁、枳椇子提取物、葛根提取物、车前草提取物混合均匀:35%刺梨原汁、1.5%提取物(枳椇子提取物:葛根提取物:车前草提取物=1:2:1.5)。
(4)灌装:将上述混合好的提取物混合液分别灌装于30mL玻璃瓶中;
(5)杀菌:将上述灌装好的半成品进行高温杀菌后得到成品护肝醒酒组合物(ZHW)。用于后续研究。
1.3.2实验动物分组及给药
60只SPF级健康雄性KM小鼠,质量为18~22g,购于重庆腾鑫生物技术有限公司,许可证号:SCXK(京)2019-0010,质量合格证号:No.110324220107230451,动物饲养条件(温度:22±2℃;相对湿度:55±5%;每天光照12h;自由进食和饮水)符合本研究中心的制定的伦理学要求。
动物分组设为空白组(K)、模型组(M)、阳性组(Y)、ZHW低(D)、中(Z)、高剂量(G)组每组10只。空白组与模型组小鼠每天按10mL/kg灌胃生理盐水;阳性组,每天按60mg/kg灌胃水飞蓟宾胶囊;给药组按浓度低(3mL/kg)、中(6mL/kg)、高剂量(12mL/kg)每天灌胃ZHW,持续灌胃14d,在末次灌胃6h后,除空白组灌胃生理盐水外,其他组皆按15mL/(kg·BW)灌胃53%食用酒精,建立小鼠急性酒精性肝损伤模型。
1.3.3血清生化指标测定
末次灌胃给药6h后,除空白组外其余各组灌胃53%食用酒精,禁食但不禁水12h后,将小鼠摘眼球取血,并用1.5mLEP管收集血液,静置2h,使血清充分析出,于4℃,3000r/min离心10min,吸取上清,分装,置于-80℃冰箱中冷冻保存,并参照试剂盒要求测定AST,ALT、TG的指标。
1.3.4肝脏指数测定
取血结束后,用颈椎脱臼法将小鼠处死后立即解剖,将肝脏完整取出后放入预冷的生理盐水中漂洗,将血渍洗去后,用滤纸拭干,称重,记录肝脏质量,将肝脏进行分装,放入-80℃冰箱中储存备用;根据公式(1)计算各组肝脏指数。
式中:
W--肝脏指数,%;
m1--小鼠肝脏质量,g;
m2--小鼠体重,g。
1.3.5肝组织指标测定
取各组小鼠的肝组织按照质量与体积比1:9的比例加入预冷的生理盐水,放入匀浆机中充分研磨以制备10%肝组织匀浆,4℃、3500r/min离心,吸取上清液,分装,并按照试剂盒要求测定其ALDH、ADH、SOD、MDA水平。
1.3.6肝脏组织病理学考察
取各组小鼠肝脏组织的同一部位,用提前预冷的生理盐水将表面多余的血渍冲去,滤纸擦干,并置于4%(v/v)组织固定液中固定24h以上,经洗涤脱水、石蜡包埋、切片、苏木精和伊红染色后制成切片,置于光学显微镜下观察肝组织的病理形态学变化,拍照记录。
1.4数据处理
SPSS26.0分析数据并用GraphPad Prism 6.01软件作图,数据结果均以“mean±SD”表示。两组间的均数比较采用单因素方差分析,P<0.05表示差异显著,P<0.01表示差异极显著。
2.结果与讨论
2.1 ZHW对小鼠肝脏指数的影响
酒精代谢摄入体内主要在肝脏中进行代谢,代谢不充分时,便会在体内发生一系列的化学反应(氧化应激和脂质过氧化反应),对肝脏造成一定的毒性和损伤[15,16],使脏器发生肿大,常以肝脏指数作为衡量肝脏肿大的指标[17]。由图1可看出,与空白组相比,模型组肝脏指数显著升高29.50%,表示酒精代谢不畅,使脂质代谢发生紊乱,脂肪变性堆积,对肝脏造成损伤,使肝脏发生肿大。与模型组相比,ZHW高剂量组和阳性对照组肝脏指数均显著降低12.23%、17.48%,但低、中剂量组的肝脏指数降低不显著(P>0.05)。说明在一定剂量下ZHW能够缓解酒精对小鼠肝脏的损伤。
2.2 ZHW对小鼠血脂及血清中氨基转移酶活力的影响
ALD常常会使体内血脂代谢发生紊乱,并且摄入的酒精在体内代谢时会发生脂肪变,肝内脂肪酸氧化分解减弱并释放大量脂肪酶[18-20],促进了TG的合成,导致肝细胞中沉积的脂肪增多,造成血清TG水平异常[21];不仅如此,酒精代谢不畅使肝细胞受损,会大大增加细胞膜的通透性,肝细胞浆和线粒体中的ALT、AST会释放进入血液中,使血清中的AST、ALT含量升高[22,23]。由图2-图4可看出,与空白组相比,模型组小鼠TG含量、AST、ALT水平均显著升高154.57%、101.86%、58.77%;表明酒精导致小鼠肝细胞发生损伤,小鼠体内脂质代谢紊乱,目标模型建立成功。而与模型组相比,阳性对照组小鼠TG含量、AST、ALT活力均显著降低42.51%、31.33%、32.17%;ZHW中、高剂量组的小鼠TG含量均显著降低34.68%、48.35%;AST活力均显著降低16.65%、32.26%;ALT活力均显著降低28.71%、40.71%;低剂量组的生化指标与模型组的差异不显著(P>0.05),说明ZHW可通过降低急性酒精诱导的小鼠体内TG、AST、ALT水平,进而改善脂代谢和肝损伤。
2.3 ZHW对小鼠肝组织中酶活性和氧化损伤产物水平的影响
SOD是生物体中主要的抗氧化酶防御体系,可以有效地将机体发生氧化还原反应时产生的自由基清除,修复细胞损伤,对维持机体内自由基平衡起着至关重要的作用,其活性高低能反映肝细胞的抗氧化水平[24,25];MDA是脂质过氧化产物,是用于评价氧化应激对肝脏损害程度的指标之一[26,27],酒精在肝脏中代谢不畅时,氧化损伤产物MDA含量便会升高,诱导细胞损伤;ADH、ALDH是参与酒精在肝脏中氧化代谢最主要的两类酶,酒精摄入体内后,经ADH、ALDH催化脱氢转化为乙酸,再进一步氧化成H2O和CO2排出体外[28]。提高肝脏中的ADH和ALDH活力,加快乙醇在肝脏中的代谢分解,对肝脏的保护和ALD的防治具有重要意义。
如图5-图8,与空白组相比,模型组的SOD、ADH、ALDH水平均显著降低18.98%、61.99%、55.11%,氧化损伤产物MDA含量显著升高80.22%,小鼠出现肝细胞损伤,并且发生氧化应激,说明小鼠急性酒精性肝损伤模型建立成功。与模型组相比,阳性对照组小鼠的SOD、ADH、ALDH水平均显著升高14.62%、109.90%、51.75%;MDA的含量显著降低37.85%。ZHW低剂量组与模型组差异性不明显(P>0.05),但中、高剂量组的SOD水平均显著升高12.88%、18.61%;ADH水平均显著升高66.71%、124.61%;ALDH水平均显著升高24.56%、44.59%;其对应的MDA含量显著降低31.90%、39.10%;且呈现一定的量效关系。说明ZHW可通过降低体内MDA含量,增加体内SOD活性来改善氧化应激损伤,提高体内ADH、ALDH的活性,降低酒精对肝细胞的损伤。
2.4ZHW对小鼠肝组织病理变化的影响
肝脏组织病理学是判断肝脏受损程度的重要标准,广泛应用于各类肝损伤模型[29]。肝组织HE染色病理切片,可以观察肝组织的受损情况,是评估肝脏受损的有力证据。由图9可以看出,空白组小鼠肝细胞形态完整,排列较为规则,细胞核圆而清晰且无炎性浸润和脂肪病变,无明显空泡;模型组小鼠肝细胞发生肿胀、细胞核固缩,细胞间隙变大,局部细胞出现脂肪变性,细胞质中出现脂滴,空泡明显;ZHW低、中、高、阳性组各组肝细胞损伤较模型组均有所改善,且并未观察到明显的炎性浸润和空泡,能够一定程度的抑制病变情况。
3.结论
本实验通过构建小鼠急性酒精性肝损伤模型,从小鼠肝脏指数变化,血清和肝组织中相应生化指标以及肝脏组织病理变化等方面来探究ZHW对小鼠急性酒精性肝损伤的保护作用。研究发现ZHW可以降低急性酒精性肝损伤小鼠的肝脏指数、改善脂质代谢紊乱和肝脏的氧化损伤、提高肝脏应对氧化应激的能力,清除乙醇代谢过程中产生的有害自由基,提高抗氧化水平,促使乙醇快速代谢,保护其肝脏形态结构及功能,从而发挥解酒保肝的作用。综上,ZHW可有效预防和改善急性酒精性肝损伤,可为护肝醒酒等产品的开发提供理论依据。
虽然,上文中已经用一般性说明、具体实施方式及试验,对本发明作了详尽的描述,但在本发明基础上,可以对之作出一些修改或改进,这对本领域或技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
参考文献:
[1]王秋艳,丁慧敏,朱亚男,等.多汁乳菇多糖对小鼠急性酒精性肝损伤的保护作用[J].食品工业科技,2021,42(24):313-319.
[2]刘鑫,侯若琳,麦梦贤,等.粗毛纤孔菌子实体与菌丝体粗多糖改善小鼠急性酒精肝损伤的比较研究[J].菌物学报,2018,37(11):1532-1539.
[3]LIU X,HOU R L,YAN J J,et al.Purification and characterization ofinonotus hispidus exopolysaccharide and its protective effect on acutealcoholic liver injury in mice[J].International Journal of BiologicalMacromolecules,2019,129(15):41-49.
[4]YUAN R S,TAO X,LIANG S,et al.Protective effect of acidicpolysaccharide from schisandra chinensis on acute ethanol-induced liverinjury through reducing CYP2E1-dependent oxidative stress[J].Biomedicine&Pharmacotherapy,2018,99:537-542.
[5]吕佳敏,刘同亭,田瑛.刺梨的主要医学功效及应用研究进展[J].实用医药杂志,2018,35(4):370-372.
[6]罗鹏,龚小川,谭丽春,谢俊,等.刺梨的化学组成和药理作用研究进展[J].山东化工,2022,51(21):90-94.
[7]RENSBURGCJV,ERASMUS E,LOOTSDT,et al.Rosa roxburghiisupplementation in a controlled feeding study increases plasma antioxidantcapacity and glutathione redox state[J].European Journal of Nutrition,2005,44(7):452-457.
[8]陈醇,郝靖宇,冯昊天,等.一种枳椇子提取物、葛根提取物、益生菌配方产品醒酒及肝损伤保护作用研究[J].食品科技,2020,45(02):91-97.
[9]管咏梅,许攀,沈倩,等.葛根提取物解酒的研究进展[J].中国实验方剂学杂志,2021,27(02):210-217.
[10]许皖,李娜,柳海艳,等.基于Keap1/Nrf2/ARE信号通路探讨葛花、枳椇子提取物及其配伍对急性酒精性肝损伤小鼠抗氧化应激的作用机制[J].中国实验方剂学杂志,2023,29(01):37-44.
[11]国家药典委员会.中华人民共和国药典:2020年版一部[M].北京:中国医药科技出版社,2020:70.
[12]梁金强,陶施民,余庆涛,等.葛根提取物枳椇子提取物栀子提取物对大鼠酒精性脂肪肝的作用研究[J].药物评价研究,2018,41(11):1981-1988.
[13]李志满,邵紫君,李珊珊,等.人参枳椇子提取物提取物对小鼠酒精性肝损伤的保护作用[J].食品工业科技,2019,40(14):302-306+313.
[14]李晶,廖卫波,曾慧婷,等.车前不同部位利尿及对急性高尿酸血症大鼠保护作用的比较[J].时珍国医国药,2022,33(05):1080-1082.
[15]陈洪锁,孟宪梅.酒精性肝病分子机制的研究进展[J].包头医学院学报,2018,34(8)127-129.
[16]YANG Y M,CHO Y E,HWANG S.Crosstalk between oxidative stress andinflammatory liver injury in the pathogenesis of alcoholic liver disease[J].International Journal of Molecular Sciences.2022;23(2):774.
[17]ZHOU C Y,LAI Y L,HUANG P,et al.Naringin attenuates alcoholicliver injury by reducing lipid accumulation and oxidative stress[J].LifeSciences,2019,216:305–312.
[18]PEREZ B S,RUFIAN H,et al.Towards an improved global antioxidantresponse method(GAR plus):physiological-resembling in vitro digestion-fermentation method[J].Food Chemistry,2018,239:1253-1262.
[19]陈芮莹,林以宁.肝脏脂质代谢在非酒精性脂肪性肝病发生发展中的生物学机制[J].江西医药,2021,56(3):399-401.
[20]BIAN L,CHEN H,ZHOU X.Untargeted lipidomics analysis of morifructus polysaccharide on acute alcoholic liver injury in mice using ultraperformance liquid chromatography-quadrupole-orbitrap-high resolution massspectrometry[J].International Immunopharmacology,2021,97:107521.
[21]TESCHKE R.Alcoholic liver disease:alcohol metabolism,cascade ofmolecular mechanisms,cellular targets,and clinical aspects[J].Biomedicines,2018,6(4):106.
[22]ZHOU T,ZHANG Y J,Xu D P,et al.Protective effects of lemon juiceon alcoholindu-ced liver injury in mice[J].Biomed Research International,2017,2017(4):7463571.
[23]都梦帆,胥冰,向汝,等.苦参碱注射液对小鼠急性酒精性肝损伤的保护作用[J].中国现代医学杂志,2021,31(24):13-18.
[24]ZHANG Z,ZHOU H,BAI L,et al.Protective effects of probiotics onacute alcohol-induced liver injury in mice through alcohol metabolizingenzymes activation and hepatic TNF-αresponse reduction[J].Journal ofFunctional Foods,2019,59:234.
[25]陶施民,卢贤欢,郭雅娟,等.葛根提取物枳椇子提取物栀子胶囊解酒护肝功效研究[J].中医药导报,2018,24(10):19-22.
[26]王英,刘慧芳,楼招欢.抹茶对实验性小鼠急性酒精性肝损伤的干预作用研究[J].浙江中西医结合杂志,2019,29(1):25-27.
[27]SALOMONE F,BARBAGALLO I,PUZZO L,et al.Efficacy of adiposetissuemesenchymal stem cell transplantation in rats with acetaminophen liverinjury[J].Stem Cell Res,2013,11(3):1037-1044.
[28]ENG M Y,LUCZAK S E,WALL T L.Aldh2,Adh1b,and Adh1c genotypes inAsians:a literature review[J].Alcohol Res Health,2007,30(1):22-27.
[29]李园园,郝海波,刘加洪,等.益生菌补充改善吡嗪酰胺致大鼠肝损伤及肠道菌群紊乱的效果[J].食品科学,2018,39(13):159-165.
Claims (10)
1.一种护肝醒酒组合物,其特征在于,所述组合物由以下重量份的原料组成:刺梨原汁30-40份、葛根提取物0.1-0.5份、枳椇子提取物0.3-0.9份、车前草提取物0.2-0.8份、水58-69份。
2.一种护肝醒酒组合物,其特征在于,所述组合物由以下重量份的原料组成:刺梨原汁32-38份、葛根提取物0.2-0.4份、枳椇子提取物0.5-0.7份、车前草提取物0.4-0.6份、水61-66份。
3.一种护肝醒酒组合物,其特征在于,所述组合物由以下重量份的原料组成:刺梨原汁35份、葛根提取物0.33份、枳椇子提取物0.67份、车前草提取物0.5份、水63.5份。
4.一种如权利要求1-3任一项所述的护肝醒酒组合物的制备方法,其特征在于,包括如下步骤:
(1)刺梨原汁的制备:挑选品质优良,无病虫害的刺梨鲜果经清洗干净、物理破碎、低温物理压榨、过滤后得到刺梨原汁;
(2)提取物制备:
枳椇子提取物以65-75%乙醇作为提取溶剂,料液比1:8-12提取1-3次,0.5-1.5h/次,滤液减压浓缩,干燥得到枳椇子提取物;
车前草提取物以去离子水作为提取溶剂,料液比1:4-8提取1-3次,0.5-1.5h/次,滤液减压浓缩,干燥得到车前草提取物;
葛根提取物以75-85%乙醇作为提取溶剂,料液比1:8-12提取1-3次,0.5-1.5h/次,滤液减压浓缩,干燥得到葛根提取物;
(3)混合:将刺梨原汁、枳椇子提取物、葛根提取物、车前草提取物与水按组方量混合均匀;
(4)灌装:将上述混合好的提取物混合液分别灌装于30mL玻璃瓶中;
(5)杀菌:将上述灌装好的半成品进行高温杀菌后得到成品护肝醒酒组合物。
5.根据权利要求4所述的制备方法,其特征在于,所述步骤(2)提取物制备为:枳椇子提取物以70%乙醇作为提取溶剂,料液比1:10提取2次,1h/次,滤液减压浓缩,干燥得到枳椇子提取物提取物;车前草提取物以去离子水作为提取溶剂,料液比1:4提取2次,1h/次,滤液减压浓缩,干燥得到车前草提取物提取物;葛根提取物以80%乙醇作为提取溶剂,料液比1:10提取2次,1h/次,滤液减压浓缩,干燥得到葛根提取物提取物。
6.根据权利要求4所述的制备方法,其特征在于,步骤(3)混合中所述刺梨原汁、提取物的质量占比为:35%刺梨原汁、1.5%提取物;所述提取物中枳椇子提取物提取物、葛根提取物提取物、车前草提取物提取物的质量比为:枳椇子提取物提取物:葛根提取物提取物:车前草提取物提取物=1:2:1.5。
7.根据权利要求4所述的制备方法,其特征在于,步骤(4)中所述高温杀菌条件为:温度85℃,杀菌时间25分钟。
8.如权利要求1-3任一项所述的护肝醒酒组合物或权利要求4-7任一项所述的制备方法制备所得的成品护肝醒酒组合物在制备醒酒、护肝的饮料中的应用。
9.如权利要求1-3任一项所述的护肝醒酒组合物或权利要求4-7任一项所述的制备方法制备所得的成品护肝醒酒组合物在制备醒酒、护肝的保健食品中的应用。
10.如权利要求1-3任一项所述的护肝醒酒组合物或权利要求4-7任一项所述的制备方法制备所得的成品护肝醒酒组合物在制备醒酒药物、预防或治疗护肝损伤药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311326995.6A CN117297005A (zh) | 2023-10-13 | 2023-10-13 | 一种护肝醒酒组合物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311326995.6A CN117297005A (zh) | 2023-10-13 | 2023-10-13 | 一种护肝醒酒组合物及其制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117297005A true CN117297005A (zh) | 2023-12-29 |
Family
ID=89273509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311326995.6A Pending CN117297005A (zh) | 2023-10-13 | 2023-10-13 | 一种护肝醒酒组合物及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117297005A (zh) |
-
2023
- 2023-10-13 CN CN202311326995.6A patent/CN117297005A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110574927B (zh) | 一种抗糖化组合物及其制备方法 | |
CN103142720B (zh) | 黑树莓提取物在制备抗糖尿病药物中的应用 | |
CN109329500A (zh) | 一种茯砖茶多酚和多糖的复合速溶茶及其制备方法和应用 | |
CN108434248B (zh) | 一种枸杞活性成分的提取方法及用途 | |
CN116036194A (zh) | 一种中药组合物、葡萄酒及其制备方法和应用 | |
CN109601795A (zh) | 以赶黄草为主要原料的组合物解酒饮料及其制备方法 | |
CN113841894B (zh) | 黑果枸杞花青素提取物及冻干粉的制备方法和在抗氧化和抗衰老产品中的应用 | |
CN1861637A (zh) | 淮山药多糖制备方法及其用途 | |
KR101501233B1 (ko) | 흑차 에탄올 수용액 냉침 추출물을 함유하는 체중 및 체지방 감소 또는 지질관련 대사성 질환의 예방 또는 개선용 약학적 조성물 및 건강식품 | |
CN116712358A (zh) | 一种用于皮肤的复方精油和含有其的药物组合物 | |
CN115844920A (zh) | 长茎葡萄蕨藻多糖在制备治疗骨质疏松症药物中的应用 | |
CN117297005A (zh) | 一种护肝醒酒组合物及其制备方法与应用 | |
CN109602759A (zh) | 罗汉松实多糖的用途 | |
CN113694104B (zh) | 一种对化学性肝损伤有保护作用、促进肝脏再生的中药组合物、制备方法及其用途 | |
CN117500842A (zh) | Cs-4发酵菌丝体杂聚多糖及其制备方法与用途 | |
CN113730466A (zh) | 一种黑莓提取物的制备方法及其应用 | |
CN101757059B (zh) | 从植物中提取α-葡萄糖苷酶活性抑制剂的方法 | |
CN101638444B (zh) | 海滨锦葵多糖制备工艺及用途 | |
CN101804083B (zh) | 松花粉及其提取物在治疗炎症性肠病中的用途及该提取物的制备方法 | |
CN101804128B (zh) | 一种治疗炎症性肠病的药物组合物及该组合物在制备治疗炎症性肠病药物中的用途 | |
CN111544440A (zh) | 地奥司明及组合物在制备抗肥胖的产品方面中的应用 | |
CN110882319A (zh) | 衢枳壳、衢枳壳提取物和含有他们的产品在预防和/或治疗代谢性肝病中的应用 | |
CN1233649C (zh) | 化合物-巴戟甲素及其制法和用途 | |
CN111700903B (zh) | 一种紫菜多糖的应用及紫菜多糖的制备方法 | |
CN103083376B (zh) | 可用于治疗鼻炎的藁本提取物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |